Table 1.
Clinical Characteristics of Study Subjects
| Variables | COVID-19 patients | Pneumonia patients | Healthy controls |
|---|---|---|---|
| Number | 30 | 9 | 30 |
| Male | 16 (53) | 5 (56) | 15 (50) |
| Age, y | 46 (29, 63) | 63 (47,69) | 34 (23, 48) |
| Comorbidities | 11 (37) | 9 (100) | 0 (0) |
| Recent exposure history | |||
| Tzravel to Wuhan City | 0 (0) | 0 (0) | |
| Travel to other cities of Hubei province | 1 (7) | 0 (0) | |
| Contact with person with COVID-19 | 9 (30) | 0 (0) | |
| Have family cluster outbreak | 4 (13) | 0 (0) | |
| Symptoms at admission | |||
| Fever | 17 (57) | 6 (67) | |
| Gastrointestinal symptoms | |||
| Diarrhea | 4 (13) | 2 (22) | |
| Respiratory symptoms | |||
| Cough | 20 (67) | 6 (67) | |
| Sputum | 9 (30) | 5 (56) | |
| Sore throat | 4 (13) | 0 (0) | |
| Rhinorrhea | 5 (17) | 1 (11) | |
| Shortness of breath | 4 (13) | 3 (33) | |
| Blood result | |||
| Lymphocytes (x 109/L, normal range 1.1–2.9) | 1 (0.8, 1.375) | 1 (0.6, 1.2) | |
| Antibiotics therapy | 16 (53) | 100 (100) | |
| 1 type of antibiotics | 6 (20) | 2 (22) | |
| 2 types of antibiotics | 7 (23) | 4 (44) | |
| 3 types of antibiotics | 3 (10) | 3 (33) | |
| Antiviral therapy | 20 (67) | 0 (0) | |
| Kaletra | 19 (63) | 0 (0) | |
| Ribavirin | 12 (40) | 0 (0) | |
| Interferon beta-1b | 3 (10) | 0 (0) | |
| Death | 0 (0) | 0 (0) |
Values are expressed in number (percentage) and median (interquartile range).